ZLDPF (Zealand Pharma AS) Tariff Resilience Score: 7/10 (As of Jul. 01, 2026)


ZLDPF Zealand Pharma AS ZLDPF
62 GF Score
Price $43.77
GF Value $1,914.49
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Zealand Pharma AS Tariff Resilience Score?

Zealand Pharma AS ZLDPF 62 Tariff Resilience Score is 7 as of Jul. 01, 2026. GuruFocus rates ZLDPF with a GF Score™ of 62/100 and a GF Value™ of $1,914.49 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,374 Biotechnology companies, Zealand Pharma AS ranks better than 90.39% on this metric.

Zealand Pharma AS has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Zealand Pharma AS has Zealand Pharma's operations are primarily in Europe, with limited exposure to US-China tariffs. Its focus on biotech reduces direct tariff impacts, and it has strong pricing power. Historical tariff changes have had minimal impact on its operations.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Zealand Pharma AS might have Highly Resilient.

Zealand Pharma AS  (OTCPK:ZLDPF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Zealand Pharma AS Tariff Resilience Score Related Terms

ZLDPF vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Zealand Pharma AS's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zealand Pharma AS Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's Tariff Resilience Score falls into.


ZLDPF
62GF Score
Zealand Pharma AS ZLDPF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Zealand Pharma AS (ZLDPF) has a Tariff Resilience Score of 7 as of Jul. 01, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Zealand Pharma AS ranks #132 out of 1374 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Zealand Pharma AS's Tariff Resilience Score too high?
Zealand Pharma AS's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Zealand Pharma AS's value of 7 is 75% above this industry median. Based on the distribution chart, Zealand Pharma AS ranks #132 out of 1374 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zealand Pharma AS has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zealand Pharma AS ranks #132 out of 1374 companies for Tariff Resilience Score. This places Zealand Pharma AS in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Zealand Pharma AS's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,374 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zealand Pharma AS's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zealand Pharma AS's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (ZLDPF) is currently considered Possible Value Trap. The stock's GF Value™ is $1,914.49, compared to a current price of $43.77 — trading 97.7% below its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Zealand Pharma AS's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current Tariff Resilience Score is 7 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zealand Pharma AS (ZLDPF) Overvalued in 2026?

Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued. The current stock price of $43.77 is trading 97.7% below its estimated GF Value™ of $1,914.49. GuruFocus considers Zealand Pharma AS to be Possible Value Trap.

Key valuation signals for ZLDPF:

  • Tariff Resilience Score: 7
  • GF Value™: $1,914.49 vs. price of $43.77 (97.7% below fair value)
  • GF Score™: 62/100 with 3 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1374)

No single metric tells the full story. See the ZLDPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
62GF Score

Get the complete analysis for ZLDPF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$43.77
Price
$1,914.49
GF Value